OmniComm selected EDC "vendor of choice" by leading East Coast based Biotech for Phase II Central Nervous System Study

Fort Lauderdale, FL, March 3, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions, has been selected by an east coast biotechnology company as "vendor of choice" to perform electronic data capture (EDC) for an upcoming Phase II clinical study focusing on a central nervous system disorder. This is a new account for OmniComm, and this first contract is in excess of $300,000. The company believes that the client plans to run additional studies on the TrialMaster™ platform throughout 2010.

"OmniComm is pleased to have been selected to provide EDC for another prestigious client," said Stephen Johnson, COO of OmniComm Systems. "We continue to work toward maintaining our reputation for service and support, and providing EDC solutions proven to accommodate complex study designs."

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large-scale institutions to efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT: Stephen Johnson at: + 1 954-377-1726

Back